Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice : The APALUSA Study
Barrios, Vivencio (Hospital Universitario Ramón y Cajal (Madrid))
Escobar, Carlos (Hospital Universitario La Paz (Madrid))
Suárez Fernández, Carmen (Hospital Universitario de la Princesa (Madrid))
Garcia-Moll, Xavier (Institut d'Investigació Biomèdica Sant Pau)
Lozano Sánchez, Francisco (Hospital Clínico Universitario (Salamanca))

Data:	2022
Resum:	This study was aimed to ascertain the clinical profile and management of patients with ischemic heart disease (IHD) and/or peripheral artery disease (PAD). In this observational and cross-sectional study developed in 80 hospitals throughout Spain, consecutive adults with stable IHD and/or PAD were included. A total of 1089 patients were analyzed, of whom 65. 3% had only IHD, 17. 8% PAD and 16. 9% both. A total of 80. 6% were taking only one antiplatelet agent, and 18. 2% were on dual antiplatelet therapy (mainly aspirin/clopidogrel). Almost all patients were taking 1 lipid lowering drug, mainly moderate-to-high intensity statins. IHD patients took ezetimibe more commonly than PAD (43. 9% vs. 12. 9%; p < 0. 001). There were more patients with IHD that achieved blood pressure targets compared to PAD (<140/90 mmHg: 67. 9% vs. 43. 0%; p < 0. 001; <130/80 mmHg: 34. 1% vs. 15. 7%; p < 0. 001), LDL-cholesterol (<70 mg/dL: 53. 1% vs. 41. 5%; p = 0. 033; <55 mg/dL: 26. 5% vs. 16. 0%; p = 0. 025), and diabetes (HbA1c < 7%, with SGLT2i/GLP1-RA: 21. 7% vs. 8. 8%; p = 0. 032). Modifications of antihypertensive agents and lipid-lowering therapy were performed in 69. 0% and 82. 3% of patients, respectively, without significant differences between groups. The use of SGLT2i/GLP1-RA was low. In conclusion, cardiovascular risk factors control remains poor among patients with IHD, PAD, or both. A higher use of combined therapy is warranted.
Nota:	Altres ajuts: Bayer Hispania S.L.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Antiplatelet therapy ; Blood pressure ; Cardiovascular ; Diabetes ; Ischemic heart disease ; LDL cholesterol ; Peripheral artery disease
Publicat a:	Journal of clinical medicine, Vol. 11 Núm. 12 (June 2022) , p. 3554, ISSN 2077-0383

DOI: 10.3390/jcm11123554
PMID: 35743622

14 p, 423.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats